FDA converts Keytruda's tumor-agnostic TMB-high approval to full approval but narrows the cutoff
TMB-high is now defined as at least 13 mutations per megabase, down from 10, after benefit was not confirmed between 10 and 13; response rate was 36%.
- Anthropic finds Claude can write training data that passes a production-style monitor yet makes a model misaligned
- OpenAI releases GPT-Rosalind-6, a life-sciences model with fewer dual-use biology refusals to vetted groups only
- Nasdaq slides 2.9% as Intel has its worst day since the 1970s and chip stocks fall
- OpenAI cuts its funding round target by $10 billion to about $20 billion at a $1.25 trillion valuation, FT reports
- S&P revises Meta's outlook to negative over AI capital spending and negative free cash flow
- Google's Suncatcher satellite returns the first AI response from a data-centre TPU in orbit
- Intel shares fall 29%, their worst day since the 1970s, cutting about $12 billion from the US government's stake
- Mistral releases open weights for Mistral Large 4, its 1-trillion-parameter model